Education
About Us
Working with TipRanks
Follow Us
ImmunoCellular Therapeutics (IMUC)
OTHER OTC:IMUC
IMUC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.01 - $0.21
Previous CloseN/A
Volume63.00
Average Volume (3M)642.00
Market Cap
$8.75M
Enterprise Value$9.07M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.35
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,270,750
10 Day Avg. Volume1,001
30 Day Avg. Volume642
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)-14.34
Price to Sales (P/S)0.00
P/FCF Ratio-3.25
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
IMUC FAQ
What was ImmunoCellular Therapeutics’s price range in the past 12 months?
ImmunoCellular Therapeutics lowest stock price was $0.01 and its highest was $0.20 in the past 12 months.
What is ImmunoCellular Therapeutics’s market cap?
ImmunoCellular Therapeutics’s market cap is $8.75M.
When is ImmunoCellular Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImmunoCellular Therapeutics’s earnings last quarter?
Currently, no data Available
Is ImmunoCellular Therapeutics overvalued?
According to Wall Street analysts ImmunoCellular Therapeutics’s price is currently Overvalued.
Does ImmunoCellular Therapeutics pay dividends?
ImmunoCellular Therapeutics does not currently pay dividends.
What is ImmunoCellular Therapeutics’s EPS estimate?
ImmunoCellular Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmunoCellular Therapeutics have?
ImmunoCellular Therapeutics has 113,270,750 shares outstanding.
What happened to ImmunoCellular Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ImmunoCellular Therapeutics?
Currently, no hedge funds are holding shares in IMUC
Company Description
ImmunoCellular Therapeutics
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.
Technical Analysis
Cellectar Biosciences
―
Akari Therapeutics
―
Sensei Biotherapeutics
―
Bolt Biotherapeutics
―
Calidi Biotherapeutics
―